Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIP-AML22 Quizartinib in newly diagnosed pediatric FLT3-ITD positive, NPM1 wild-type AML
NL-OMON53485Phase 2Not yet recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of quizartinib in acute myeloid leukemia (AML), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: MRD negativity after induction and Dose-limiting toxicities and RP2D. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON53485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53485.